Clinical Trial Update: Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older). [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the safety, tolerability, and clinical outcomes of Egaten (triclabendazole) in Fascioliasis patients aged 6 years and older …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fascioliasis

Drugs mentioned

• Egaten (triclabendazole)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Fascioliasis | Phase 4 | Status: COMPLETED